| |
Safety and pharmacokinetics of DUR-928 in patients with non-alcoholic steatohepatitis-A Phase 1b study
|
| |
| |
Reported by Jules Levin
EASL 2017 April 19-23 Amsterdam Netherlands
W. KEMP1, J. SHAH2, M. J. KIM2, D. ELLIS2, J. BROWN2, F. THEEUWES2, W.Q. LIN2
1. Department of Gastroenterology, Alfred Hospital, Melbourne, Australia
2. DURECT Corporation, Cupertino, United States
|
|
| |
| |
|
|
|
